New adjunctive therapy for ischemic syndromes.
Because anticoagulant and GP IIb/IIIa inhibitors reduce mortality, myocardial ischemia, AMI, and reintervention, these agents are now becoming the standard of care for patients with USA and NQWMI. Unanswered questions remain about the best treatment regimen, appropriate dosing, long-term benefit, and cost-effectiveness of these agents, however, and many additional trials are ongoing or planned. As nurses administer these drugs, assess the patients' responses to therapy, and educate patients and families about these agents, they contribute to recent advances in preventing ischemic heart disease.
De Jong
M J
MJ
Cardiovascular Intensive Care Unit, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Texas, USA. mdejong@aol.com
Wright
S L
SL
D000925:Anticoagulants / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D016903:Drug Monitoring / Q000379:methods / Q000451:nursing; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000401:mortality / Q000451:nursing; D009730:Nursing Assessment; D010347:Patient Care Planning; D010353:Patient Education as Topic; D010975:Platelet Aggregation Inhibitors / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex